An experience of therapy of patients with chronic obstructive pulmonary disease and metabolic syndrome with selective phosphodiesterase-4 inhibitor roflumilast
https://doi.org/10.18093/0869-0189-2016-26-3-323-327
Abstract
The aim of this study was to evaluate clinical efficacy and safety of selective phosphodiesterase"4 inhibitor roflumilast in patients with COPD and metabolic syndrome.
Methods. In this prospective study, patients with stage III – IV COPD, frequent exacerbation phenotype (≥ 2 per a year) and metabolic syndrome (n = 42) were treated with roflumilast (Daxas) 500 mg q.d. additionally to the basic therapy for 12 months. Clinical investigation, mMRC scale and CAT questionnaire, pulse oxymetry, spirometry, 6"min walking test, measurement of glucose, lipids and C"reactive protein in blood were used in all patients.
Results. Exacerbation rate decreased in patients with COPD treated with roflumilast. FEV1 and quality of life improved in patients treated with roflumilast. Therapy with roflumilast was associated with statistically significant reduction in the waist circumference without significant change in the body weight, waist"to"hip ratio or body mass index.
Conclusion. Therapy with roflumilast was associated with improvement in clinical, laboratory and functional parameters and reduction in exacerbation rate in patients with COPD and metabolic syndrome.
About the Authors
G. L. Ignatova
South Ural State Medical University, Healthcare Ministry of Russia: 64, Vorovskogo str., Chelyabinsk, 454092, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Department of Therapy, Faculty of Postgraduate Physician Training, South Ural State Medical University, Healthcare Ministry of Russia; tel.: (351) 7426640
E. V. Blinova
South Ural State Medical University, Healthcare Ministry of Russia: 64, Vorovskogo str., Chelyabinsk, 454092, Russia
Russian Federation
Russian Federation
PhD, Assistant Lecturer at Department of Therapy, Faculty of Postgraduate Physician Training, South Ural State Medical University, Healthcare Ministry of Russia; tel.: (351) 7428257
M. S. Bel'sner
South Ural State Medical University, Healthcare Ministry of Russia: 64, Vorovskogo str., Chelyabinsk, 454092, Russia
Russian Federation
Russian Federation
PhD student at Department of Therapy, Faculty of Postgraduate Physician Training, South Ural State Medical University, Healthcare Ministry of Russia; tel.: (351) 7428257
I. V. Grebneva
South Ural State Medical University, Healthcare Ministry of Russia: 64, Vorovskogo str., Chelyabinsk, 454092, Russia
Russian Federation
Russian Federation
PhD, Associate Professor at Department of Therapy, Faculty of Postgraduate Physician Training, South Ural State Medical University, Healthcare Ministry of Russia; tel.: (351) 7428257
References
1. Federal Clinical Guidelines on Diagnosis and Management of Chronic Obstructive Pulmonary Disease. Moscow: RRO, 2013 (in Russian).
2. Fabbri L.M., Luppi F., Beghe B., Rabe K.F. Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31: 2014–2012.
3. Loscalzo J. System’s biology and personalized medicine: a network approach to human disease. Proc. Am. Thorac. Soc. 2011; 8: 196–198.
4. Thomsen M., Dahl M., Lange P. et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186: 982–988.
5. http://www.who.int/respiratory/copd/burden/en/index.html
6. Sin D.D., Man S.F. Why are patients with COPD at increased risk of cardiovascular diseases? Circulation. 2003; 107 (11): 1514–1519.
7. Chuchalin A.G. Chronic obstructive pulmonary disease and comorbidity. Russkiy meditsinskiy zhurnal. 2008; 2: 58–64 (in Russian).
8. Chung K.F. Inflammatory mediators in chronic obstructive pulmonary disease. Curr. Drug Targets Inflamm. Allergy. 2005; 4 (6): 619–625.
9. Pinto"Plata V.M., Mullerova H., Toso J.F. et al. C"reactive protein in patients with COPD, control smokers and nonsmokers. Thorax. 2006; 61: 23–28.
10. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. The association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax. 2004; 59: 574–580.
11. Hole D.J., Watt G.C., Davey"Smith G. et al. Impaired lung function and mortality risk in men and women: findings from Renfrew and Paisley prospective population study. Br. Med. J. 1996; 313: 711–775.
12. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am. J. Crit. Care Med. 2002; 166: 333–339.
13. Sin D.D., Wu. L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population"based study and a systematic review of the literature. Chest. 2005; 127: 1952–1959.
14. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994; 272: 1497–1505.
15. Heindl S., Lehnert M., Criee C.P. et al. Marked sympathetic activation in patients with chronic respiratory failure. Am. J. Respir. Crit. Care Med. 2001; 164: 597–601.
16. Verma S., Li S.H., Badiwala M.V. et al. Endothelin antagonism and interleukin"6 inhibition attenuate the proatherogenoc effects of C"reactive protein. Circulation. 2002; 105: 1890–1896.
17. Wellen K.E., Hotamisligil G.S. Inflamation, stress and diabetes. J. Clin. Invest. 2005; 115: 1111–1119.
18. Boswell"Smith V., Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD"focus on roflumilast. Int. J. Chron. Obstruct. Pulm. Dis. 2007; 2 (2): 121–129.
Review
For citations:
Ignatova G.L., Blinova E.V., Bel'sner M.S., Grebneva I.V. An experience of therapy of patients with chronic obstructive pulmonary disease and metabolic syndrome with selective phosphodiesterase-4 inhibitor roflumilast. PULMONOLOGIYA. 2016;26(3):323-327. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-3-323-327
Views:
889
Email this article 